Inactive Instrument

News Amylin Pharmaceuticals LLC

Stocks

US0323461089

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

12-08-02	Bristol Myers Squibb Co. : Bristol-Myers executive charged with insider trading	RE
12-07-16	BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion	RE

All News

Mentions Relevance

12-08-09	Amylin Pharmaceuticals, Inc. : Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin	PU
12-07-11	Amylin Pharmaceuticals, Inc. : The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Amylin Pharmaceuticals, Inc. in Connection with the Sale of the Company to Bristol-Myers Squibb Corporation	BU
12-07-09	Amylin Pharmaceuticals, Inc. : Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Amylin Pharmaceuticals, Inc.	PR
12-07-07	Amylin Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.	BU
12-07-03	Amylin Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.	PR
12-07-03	Amylin Pharmaceuticals, Inc. : Ryan & Maniskas, LLP Announces Investigation of Amylin Pharmaceuticals, Inc.	BU
12-07-02	Amylin Pharmaceuticals, Inc. : The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Amylin Pharmaceuticals, Inc. in Connection with the Sale of the Company to Bristol-Myers Squibb Corporation	BU
12-07-02	Amylin Pharmaceuticals, Inc. : Rigrodsky & Long, P.A. Announces Investigation Of Amylin Pharmaceuticals, Inc. Buyout	BU
12-06-25	Amylin Pharmaceuticals, Inc. : New Clinical Data Analyses Show Metreleptin Reduced Blood Glucose and Triglyceride Levels in Patients with Rare Forms of Lipodystrophy	BU
12-06-09	Amylin Pharmaceuticals, Inc. : SYMLIN® Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range	BU
12-06-09	Amylin Pharmaceuticals, Inc. : BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes	BU
12-06-04	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present Data on BYDUREON™, BYETTA® and SYMLIN® at the American Diabetes Association 2012 Meeting	BU
12-05-29	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference and Goldman Sachs 33rd Annual Global Healthcare Conference	BU
12-05-08	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders	BU
12-04-30	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present at Deutsche Bank 37th Annual Health Care Conference	BU
12-04-26	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals Reports First Quarter 2012 Financial Results	BU
12-04-19	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Webcast First Quarter Results	BU
12-04-09	Amylin Pharmaceuticals, Inc. : Icahn sues Amylin, pushes for sale	RE
12-04-03	Amylin Pharmaceuticals, Inc. : Amylin Completes Biologics License Application for Metreleptin to Treat Diabetes and/or Hypertriglyceridemia in Patients With Rare Forms of Lipodystrophy	PR
12-03-28	Amylin Pharmaceuticals, Inc. : Amylin rejected $3.5 billion Bristol offer: Bloomberg	RE
12-03-23	Amylin Pharmaceuticals, Inc. : BYETTA® Approved for Use with Basal Insulin in Europe	PU
12-03-08	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals Announces Pricing of Public Offering of Common Stock	PR
12-03-08	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference	PR
12-03-07	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals Announces Public Offering of Common Stock	PR
12-02-29	Amylin Pharmaceuticals, Inc. : Amylin Supports Rare Disease Day 2012	PR